This is a rights consolidation move with no disclosed financial terms, making near-term revenue impact unquantifiable. Monitor for separate definitive agreements on additional ex-US territories and for any Apitox clinical or commercialization milestones that would trigger the royalty stream.
Price Chart
Executive Summary
Apimeds Pharmaceuticals US (APUS) entered into an Assignment and Transfer Agreement with FreeT Inc. to acquire certain Apitox-related rights, including 100% of Korean medicine clinic rights in South Korea, a 25% royalty on US Apitox commercialization, and a 25% revenue participation on overseas rights. No upfront or milestone payments were disclosed, and the agreement excludes underlying IP ownership and global rights not held by FreeT. FreeT also expressed intent to support future global commercialization and potentially grant additional ex-US Apitox rights to APUS under separate agreements.
Key Facts
- APUS acquired 100% of Apitox rights for Korean medicine clinics in South Korea from FreeT Inc.
- APUS obtained a 25% royalty entitlement on US Apitox commercialization proceeds.
- APUS obtained a 25% revenue participation right on net proceeds from overseas rights agreements.
- No upfront payment, milestone payments, or deal value were disclosed in the filing.
- The assignment excludes underlying IP ownership, global rights not held by FreeT, and any manufacturing/regulatory rights.
- FreeT expressed intent to support future global commercialization and potentially grant additional ex-US Apitox rights to APUS.
Financial Impact
No upfront or milestone payments disclosed; 25% royalty on US Apitox proceeds and 25% revenue participation on overseas rights — monetization timeline uncertain.
Risk Factors
- No upfront or milestone payments disclosed — value of the acquired rights is entirely contingent on future Apitox commercialization.
- Assignment excludes underlying IP and global rights not held by FreeT, limiting APUS's control over the asset.
- FreeT's commitment to facilitate future transactions is subject to separate definitive agreements with no guarantee of completion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-092680 |
| Document: ea030307601ex10-1.htm | 0001213900-26-092680 |
| Document: 0001213900-26-092680-index-headers.html | 0001213900-26-092680 |
| Document: 0001213900-26-092680-index.html | 0001213900-26-092680 |
| Document: 0001213900-26-092680.txt | 0001213900-26-092680 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | Press Release | $4.62 | awaiting T+60 | — | $2.89 (−37.34%) |
Oct 13, 2026 14d ago | 8-K | $4.62 | awaiting T+60 | — | $2.89 (−37.34%) |
Oct 1, 2026 26d ago | 8-K | $4.10 | awaiting T+60 | — | $2.89 (−29.39%) |
Sep 22, 2026 5w ago | 8-K | $2.29 | awaiting T+60 | — | $2.89 (+26.42%) |
Aug 21, 2026 9w ago | 8-K | $4.75 | awaiting T+60 | — | $2.89 (−39.05%) |
Aug 6, 2026 11w ago | 8-K | $4.23 | awaiting T+60 | — | $2.89 (−31.56%) |
May 5, 2026 25w ago | 8-K | $30.00 $4.92 | ▼ −83.60% | ▼ −86.34% | $2.89 (−90.35%) |
May 4, 2026 25w ago | 8-K | $1.88 $5.75 | ▼ −205.85% | ▼ −203.99% | $2.89 (−53.99%) |
Apr 16, 2026 27w ago | 8-K | $1.88 $0.7324 | ▲ +61.04% | ▲ +67.19% | $2.89 (−53.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers